Awachana Jiamsakul1, Iskandar Azwa2, Fujie Zhang3, Evy Yunihastuti4, Rossana Ditangco5, Nagalingeswaran Kumarasamy6, Oon Tek Ng7, Yu-Jiun Chan8, Penh Sun Ly9, Jun Yong Choi10, Man-Po Lee11, Sanjay Pujari12, Sasisopin Kiertiburanakul13, Romanee Chaiwarith14, Tuti Parwati Merati15, Shashikala Sangle16, Suwimon Khusuwan17, Benedict Lh Sim18, Anchalee Avihingsanon19, Cuong Duy20, Junko Tanuma21, Jeremy Ross22, Matthew Law1, Treat Asia Hiv Observational Database Of IeDEA Asia-Pacific. 1. The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. 2. University of Malaya Medical Centre, Kuala Lumpur, Malaysia. 3. Beijing Ditan Hospital, Capital Medical University, Beijing, China. 4. Working Group on AIDS, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia. 5. Research Institute for Tropical Medicine, Manila, Philippines. 6. Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), The Voluntary Health Services (VHS), Chennai, India. 7. Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore. 8. Taipei Veterans General Hospital, Taipei, Taiwan. 9. National Center for HIV/AIDS, Dermatology & STDs, and University of Health Sciences, Phnom Penh, Cambodia. 10. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 11. Queen Elizabeth Hospital, Yau Ma Tei, Hong Kong SAR, China. 12. Institute of Infectious Diseases, Pune, India. 13. Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 14. Research Institute for Health Sciences, Chiang Mai, Thailand. 15. Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia. 16. BJ Government Medical College and Sassoon General Hospital, Pune, India. 17. Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand. 18. Hospital Sungai Buloh, Sungai Buloh, Malaysia. 19. HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 20. Bach Mai Hospital, Hanoi, Vietnam. 21. National Center for Global Health and Medicine, Tokyo, Japan. 22. TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Abstract
BACKGROUND: The World Health Organization recommends continuation with the failing second-line regimen if third-line option is not available. We investigated treatment outcomes among people living with HIV in Asia who continued with failing second-line regimens compared with those who had treatment modifications after failure. METHODS: Treatment modification was defined as a change of two antiretrovirals, a drug class change or treatment interruption (TI), all for >14 days. We assessed factors associated with CD4 changes and undetectable viral load (UVL <1,000 copies/ml) at 1 year after second-line failure using linear and logistic regression, respectively. Survival time was analysed using competing risk regression. RESULTS: Of the 328 patients who failed second-line ART in our cohorts, 208 (63%) had a subsequent treatment modification. Compared with those who continued the failing regimen, the average CD4 cell increase was higher in patients who had a modification without TI (difference =77.5, 95% CI 35.3, 119.7) while no difference was observed among those with TI (difference =-5.3, 95% CI -67.3, 56.8). Compared with those who continued the failing regimen, the odds of achieving UVL was lower in patients with TI (OR=0.18, 95% CI 0.06, 0.60) and similar among those who had a modification without TI (OR=1.97, 95% CI 0.95, 4.10), with proportions of UVL 60%, 22% and 75%, respectively. Survival time was not affected by treatment modifications. CONCLUSIONS: CD4 cell improvements were observed in those who had treatment modification without TI compared with those on the failing regimen. When no other options are available, maintaining the same failing ART combination provided better VL control than interrupting treatment.
BACKGROUND: The World Health Organization recommends continuation with the failing second-line regimen if third-line option is not available. We investigated treatment outcomes among people living with HIV in Asia who continued with failing second-line regimens compared with those who had treatment modifications after failure. METHODS: Treatment modification was defined as a change of two antiretrovirals, a drug class change or treatment interruption (TI), all for >14 days. We assessed factors associated with CD4 changes and undetectable viral load (UVL <1,000 copies/ml) at 1 year after second-line failure using linear and logistic regression, respectively. Survival time was analysed using competing risk regression. RESULTS: Of the 328 patients who failed second-line ART in our cohorts, 208 (63%) had a subsequent treatment modification. Compared with those who continued the failing regimen, the average CD4 cell increase was higher in patients who had a modification without TI (difference =77.5, 95% CI 35.3, 119.7) while no difference was observed among those with TI (difference =-5.3, 95% CI -67.3, 56.8). Compared with those who continued the failing regimen, the odds of achieving UVL was lower in patients with TI (OR=0.18, 95% CI 0.06, 0.60) and similar among those who had a modification without TI (OR=1.97, 95% CI 0.95, 4.10), with proportions of UVL 60%, 22% and 75%, respectively. Survival time was not affected by treatment modifications. CONCLUSIONS: CD4 cell improvements were observed in those who had treatment modification without TI compared with those on the failing regimen. When no other options are available, maintaining the same failing ART combination provided better VL control than interrupting treatment.
Authors: F Fily; E Ayikobua; D Ssemwanga; S Nicholas; P Kaleebu; C Delaugerre; E Pasquier; I Amoros Quiles; S Balkan; B Schramm Journal: Trop Med Int Health Date: 2018-10 Impact factor: 2.622
Authors: Matthew P Fox; Rebecca Berhanu; Kim Steegen; Cindy Firnhaber; Prudence Ive; David Spencer; Sello Mashamaite; Sadiyya Sheik; Ingrid Jonker; Pauline Howell; Lawrence Long; Denise Evans Journal: Trop Med Int Health Date: 2016-07-07 Impact factor: 2.622
Authors: J Zhou; P C K Li; N Kumarasamy; M Boyd; Y M A Chen; T Sirisanthana; S Sungkanuparph; S Oka; G Tau; P Phanuphak; V Saphonn; F J Zhang; S F S Omar; C K C Lee; R Ditangco; T P Merati; P L Lim; J Y Choi; M G Law; S Pujari Journal: HIV Med Date: 2009-07-06 Impact factor: 3.180
Authors: Maya L Petersen; Linh Tran; Elvin H Geng; Steven J Reynolds; Andrew Kambugu; Robin Wood; David R Bangsberg; Constantin T Yiannoutsos; Steven G Deeks; Jeffrey N Martin Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: Helen Bell Gorrod; Richard Court; Michael Schomaker; Gary Maartens; Richard A Murphy Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771
Authors: Victor Ssempijja; Gertrude Nakigozi; Larry Chang; Ron Gray; Maria Wawer; Anthony Ndyanabo; Jingo Kasule; David Serwadda; Barbara Castelnuovo; Anja Van't Hoog; Steven James Reynolds Journal: BMC Infect Dis Date: 2017-08-22 Impact factor: 3.090
Authors: Denise Evans; Kamban Hirasen; Rebecca Berhanu; Given Malete; Prudence Ive; David Spencer; Sharlaa Badal-Faesen; Ian M Sanne; Matthew P Fox Journal: AIDS Res Ther Date: 2018-04-10 Impact factor: 2.250